Page last updated: 2024-11-07

phosphocitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phosphocitrate: potent inhibitor of hydroxylapatite crystal growth in medium supersaturated with respect to Ca(2+) & phosphate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123745
SCHEMBL ID73267
MeSH IDM0062450

Synonyms (9)

Synonym
1,2,3-propanetricarboxylic acid, 2-(phosphonooxy)-
phosphocitrate
2-phosphonooxypropane-1,2,3-tricarboxylic acid
2565-87-9
AKOS005762856
SCHEMBL73267
DTXSID30180349
2-phosphonooxy-1,2,3 propanetricarboxylic acid
FT-0715939

Research Excerpts

Overview

Phosphocitrate is a powerful inhibitor of biological crystallization. It is a potential disease modifying drug for crystal associated diseases such as crystals associated osteoarthritis [OA].

ExcerptReferenceRelevance
"Phosphocitrate [PC] is a powerful inhibitor of biological crystallization and a potential disease modifying drug for crystal associated diseases such as crystals associated osteoarthritis [OA]. "( Inhibition of calcium phosphate-DNA coprecipitates induced cell death by phosphocitrates.
Cheung, HS; Demadis, KD; Reuben, P; Sallis, JD; Sun, Y; Wenger, L, 2005
)
2
"Phosphocitrate, which is a poor chelator of Ca2+, did not reduce the hypercalcemia induced by either agent."( Phosphocitrate inhibits mitochondrial and cytosolic accumulation of calcium in kidney cells in vivo.
Howard, JE; Lehninger, AL; Malis, CD; Tew, WP, 1981
)
2.43
"Phosphocitrate (PC) is a recognized in vitro inhibitor of hydroxyapatite and calcium oxalate monohydrate crystal formation, but it is not known whether PC can similarly restrict CPPD crystal development."( Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate.
Cheung, HS; Kurup, IV; Ryan, LM; Sallis, JD, 1996
)
1.23

Effects

ExcerptReferenceRelevance
"Phosphocitrate structure has been resolved using low temperature X-ray analysis and ab initio computational methods."( Scanning electron microscopy and molecular modeling of inhibition of calcium oxalate monohydrate crystal growth by citrate and phosphocitrate.
Madura, JD; Martin, KL; Sallis, JD; Sikes, CS; Stevens, ED; Wierzbicki, A, 1995
)
1.22

Treatment

ExcerptReferenceRelevance
"Treatment with phosphocitrate (PC) (a naturally occurring inhibitor of calcium phosphate crystallisation, which is known to block a number of HA-induced biological effects in other cell types) blocked HA-mediated mitogenesis, as well as, COX-2, MMP-1 and IL-1beta induction, at the transcriptional level."( Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.
Cooke, MM; McCarthy, GM; Morgan, MP; Sallis, JD, 2003
)
2.1

Dosage Studied

ExcerptRelevanceReference
" The formulation of a multiple emulsion preparation of phosphocitrate, however, offered an alternative delivery mode permitting infrequent dosing to be successfully investigated."( Liposome and multiple emulsion formulations augment the anticalcifying efficacy of phosphocitrate in a cutaneous calcergy model.
Kamperman, H; Sallis, JD, 1995
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (35.29)18.7374
1990's16 (31.37)18.2507
2000's11 (21.57)29.6817
2010's6 (11.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.41 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.29 (0.95)

This Compound (23.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]